Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Browse News
  • Browse Research
  • Education Catalog
  • Materials Catalog
  • HCT Presentation Slides
  • About Our Research
  • Transplant Enews

  • Medical Education & Research
  • Browse Research
  • Email
  • Print This Page

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma
+ More Topics

Subscribe to E-News

Receive new research summaries monthly.

Subscribe Now

Related Resources

Browse News
CIBMTR Research
Education Activities
Back to Top

Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

  • A safe and effective shared care approach after allogeneic HCT could be a new standard of care

    December 2022
    Abel GA, et al. – Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition showed a shared care approach after allogeneic hematopoietic cell transplantation did not compromise non-relapse mortality and may be associated with improved quality of life.

    Read More

  • Lack of collaborative relationships between physician teams associated with HCT care decisions

    April 2022

    Steffens K, et al. – Research shared at the 2022 Tandem Meetings of the ASTCT and CIBMTR presents survey outcomes from community hematology/oncology physicians regarding the strength of their relationships with local transplant centers. Community physicians with a lower self-rated relationship strength with transplant centers reported less support for early HCT treatment behaviors and lower confidence in managing patients post-transplant.

    Read More

  • Haploidentical HCT is viable alternative to matched sibling HCT in patients with AML in CR1

    July 2019
    Rashidi A, et al., Blood Advances – This large-scale retrospective study compared outcomes of adult patients with acute myeloid leukemia (AML) in first complete remission (CR1) undergoing haploidentical hematopoietic cell transplantation (HCT) (n=336) versus 869 patients who underwent matched sibling donor (MSD) HCT. Results indicate that both cohorts had comparable overall survival, leukemia-free survival, non-relapse mortality, relapse, and grade II-IV acute GVHD.

    Read More

  • Gait speed can predict survival, hospital use in older patients with blood cancers

    July 2019
    Liu MA, et al., Blood – Researchers assessing gait speed and grip strength in 314 patients aged 75 and older with MDS/leukemia, myeloma, or lymphoma found that a decrease in gait speed was significantly associated with higher mortality, increased unplanned hospitalizations, and emergency department (ED) visits. A decrease in grip strength was associated with significantly worse survival, but not hospital or ED use.

    Read More

  • Continued vigilance needed to prevent infections for HCT recipients

    January 2019

    A recent study found late fatal infections (LFI) contributed to one-third of the deaths of both adult and pediatric patients who had survived more than 2 years after allogeneic hematopoietic cell transplantation (HCT). The results highlight the importance of ongoing monitoring and preventive measures for infect

    Read More

  • Donor-derived LMP-Ts are a safe adjuvant therapy after allo HCT for EBV-associated lymphomas

    November 2018

    McLaughlin LP, et al. Blood - Autologous T cells targeting Epstein-Barr virus (EBV) latent membrane proteins (LMPs) have been shown safe and effective for the treatment of patients with type II latency EBV-associated lymphomas for whom standard therapies have failed. However, up until now, the safety and efficacy of this treatment had not been established for patients who have received an allogeneic hematopoietic cell transplant (HCT).

    Read More

  • Are the presence of post-HCT mutations in patients with MDS associated with higher risk of disease progression?

    October 2018

    Duncavage EJ, et al. N Engl J Med. – An exploratory study of 90 adults with myelodysplastic syndromes (MDS) evaluated the association of  mutations detected after allogeneic hematopoietic cell transplantation (HCT) with disease progression and survival. 

    Read More

  • Experts Highlight Latest Advances in Immunotherapies for Hematologic Diseases

    July 2018
    Paczesny S, et al. Blood – This series in the journal Blood outlines both current obstacles and new opportunities for the future on a selection of emerging immunotherapies now available to patients with hematologic diseases.

    Read More

  • Consensus Statement on HCT Late Effects Screening Guidelines in Hemoglobinopathies

    June 2018
    Shenoy S, et al. Biol Blood Marrow Transplant – An international panel of HCT experts has updated late effects screening guidelines for pediatric transplantation for hemoglobinopathies, focusing on sickle cell disease and thalassemia.

    Read More

  • Spotlight on Novel Therapies to Improve Post-HCT Graft-Versus-Leukemia Effects

    April 2018
    Zeiser R, et al. Blood – The latest research in cellular therapies, antibody-based treatments, and tyrosine kinase inhibitor (TKI)-based approaches to enhance GVL effects are outlined in articles published in a special edition of Blood.

    Read More

  • HCT and Neurocognitive Dysfunction: Recognizing Risk Factors and Developing Treatments

    March 2018
    Buchbinder D, et al. Bone Marrow Transplant – Neurocognitive dysfunction, including symptoms such as memory impairment, decreased concentration, and difficulty in performing multiple tasks simultaneously, can significantly affect hematopoietic cell transplantation (HCT) patients’ quality of life, and is a major cause of post-transplant morbidity and mortality.

    Read More

  • Lifestyle Modifications Reduce Risk of Heart Disease after HCT

    March 2018
    Leger KJ, et al. Cancer – Hematopoietic cell transplantation (HCT) survivors are at a higher risk than the general population for developing a number of adverse health issues, including heart disease.

    Read More

  • Study Identifies Key Factors Influencing the Decision to Pursue HCT for Sickle Cell Disease

    January 2018
    Khemani K, et al. Biol Blood Marrow Transplant – Currently, hematopoietic stem cell transplant (HCT) is the only treatment for sickle cell disease (SCD) with a curative intent.

    Read More

  • Allo-HCT Can Be an Effective Salvage Therapy for Multiple Myeloma

    January 2018
    Montefusco V, et al. Bone Marrow Transplant – In this study of 71 patients with multiple myeloma undergoing hematopoietic cell transplantation (HCT), 5-year overall survival (OS) was 60%, with better outcomes in patients ≤55 years and in those transplanted with chemosensitive disease.

    Read More

  • Survivorship Care Plans for HCT Recipients Reduce Cancer Treatment Distress

    December 2017
    Majhail NS, et al. ASH abstract oral presentation, December 2017 – According to results of a randomized, multicenter study, hematopoietic cell transplant (HCT) patients receiving post-transplant survivorship care plans (SCPs) had significantly lower levels of cancer treatment distress, compared to HCT recipients receiving routine post-transplant care.

    Read More

  • HCT Significantly Improves Quality of Life in Children with Sickle Cell Disease

    December 2017
    Bernaudin F, et al. ASH abstract oral presentation, December 2017 – Children with sickle cell disease (SCD) have significantly better physical health and school functioning after transplantation than do those receiving chronic transfusion, according to results of a donor/no donor study of 67 patients with SCD.

    Read More

  • Maintenance with Rituximab Prolongs Survival after Auto-HCT for Mantle Cell Lymphoma

    November 2017
    Le Gouill S, et al. N Engl J Med – Rituximab maintenance therapy after autologous hematopoietic cell transplantation (HCT) significantly prolonged event-free survival, progression-free survival, and overall survival in patients with mantle cell lymphoma, according to a phase III randomized study of 299 patients <66 years old.

    Read More

  • Report: Strategies for Overcoming Neurocognitive Dysfunction in HCT Recipients

    November 2017
    Kelly DL, et al. Biol Blood Marrow Transplant – An international panel of experts has issued a report on neurocognitive dysfunction after HCT to help clinicians understand the scope of this health-related problem, highlight its impact on the well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT.

    Read More

  • Case Studies Outline Strategies for Long-Term Monitoring of Adult HCT Survivors

    October 2017
    Bhatia S, et al. Blood – Using 4 case studies of hematopoietic cell transplantation (HCT) recipients, the authors of this “How I treat …” series in the journal Blood illustrate the challenges involved in providing long-term care for HCT survivors, and then propose several “best practice” models for risk-based screening.

    Read More

  • Palliative Care Leads to Improvements in Post-HCT Depression and PTSD

    October 2017
    El-Jawahri A, et al. J Clin Oncol – Integrating palliative care with hematopoietic cell transplantation (HCT) can improve depression and post-traumatic stress disorder (PTSD) symptoms at 6 months post-transplant according to a randomized study of 160 transplant recipients.

    Read More

  • New Patient Care Coordination Model Addresses Complexities of HCT Therapy

    September 2017
    Khera N, et al. Blood Advances – A multi-disciplinary team has proposed a care coordination framework to deliver a continuum of care to hematopoietic cell transplantation (HCT) patients.

    Read More

  • 30% of Very Young HCT Recipients Experience One or More Late Effects

    June 2017
     Vrooman LM, et al. Biol Blood Marrow Transplant - This multi-center study showed that children under 3 years old who undergo HCT are at high risk for late effects. After 1 year, 30% had developed 1 or more organ toxicity or transplant-related complication.

    Read More

  • Successful Post-HCT Immune Suppression Discontinuation Factors Identified

    April 2017
    Pidala J, et al. Biol Blood Marrow Transplant – A multi-center study of 827 hematopoietic cell transplant (HCT) recipients has identified the factors that predict successful post-HCT immune suppression discontinuation (ISD).

    Read More

  • Multi-Center Study Identifies Biomarkers Associated with HCT Outcomes

    February 2017
    Zaid MA, et al. Blood – This prospective, multi-center study confirmed the correlation of plasma-derived proteins, previously assessed only in single-center cohorts, with the potential to improve diagnosis, assess risk and manage complications after allogeneic HCT.

    Read More

  • Review: New Targeted Therapies to Treat or Prevent Chronic GVHD

    February 2017
    Cutler CS, et al. Blood – In this review, the authors summarize the current preclinical studies and early-phase clinical trial results on the following new chronic graft-versus-host disease (GVHD) therapeutic techniques. Many of these new approaches target specific immunologic pathways now known to play a role in chronic GVHD.

    Read More

  • Report: Long-Term Follow Up Needed after HCT for CLL

    January 2017
    van Gelder M, et al. Bone Marrow Transplant – Although allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for patients with chronic lymphocytic leukemia (CLL), a new study shows that HCT results in a higher mortality rate in transplant recipients compared to an age-, sex- and calendar year-matched general population.

    Read More

  • Tyrosine Kinase Inhibitor Improves Post-HCT Outcomes in Patients with AML

    December 2016
    Brunner AM, et al. Br J Haematol – In a single-center study of consecutive adults with FLT3 - internal tandem duplication (ITD) acute myeloid leukemia (AML), 29 patients transplanted in first complete remission (CR1) who received post-transplant sorafenib had significantly better outcomes than 55 patients in a control cohort.

    Read More

  • New NIH Report: Recommended Follow-Up for Long-Term Survivors after HCT

    December 2016
    Battiwalla M, et al. Biol Blood Marrow Transplant – This report outlines the recommendations issued by the National Institutes of Health (NIH) Late Effects Consensus Conference to plan the next phase of hematopoietic cell transplantation (HCT) research “to ensure that no survivor is left behind.”

    Read More

  • Adding Sirolimus to Standard GVHD Prophylaxis Significantly Reduces Acute GVHD

    December 2016
    Sandmaier B, et al. ASH abstract oral presentation, December 2016 – Adding sirolimus to a standard graft-versus-host disease (GVHD) prophylaxis of mycophenolate mofetil (MMF) and cyclosporine (CSP) can significantly reduce the risks of grades II-IV and III-IV acute GVHD and non-relapse mortality (NRM), according to results of a phase 3 multi-center randomized trial presented at ASH.

    Read More

  • Comparable HCT Survival and Incidence of Toxicity for Patients ≥60 Years

    December 2016
    Shah GL, et al. ASH abstract oral presentation, December 2016 – Survival of patients ≥60 years undergoing ex vivo CD34+ selected reduced-intensity hematopoietic cell transplantation (HCT) was comparable to that of patients <60 years, according to research presented at ASH.

    Read More

  • Evidence-Based Screening and Prevention Recommendations for Post-Transplant MetS

    October 2016
    DeFilipp Z, et al. Bone Marrow Transplant – Long-term hematopoietic cell transplant (HCT) recipients have a substantial risk (prevalence rates of 31-49% have been reported in the literature) of developing metabolic syndrome (MetS) and therefore a concurrent higher risk of cardiovascular disease, diabetes mellitus and all-cause mortality.

    Read More

  • Better 5-Year QOL after Marrow Transplant than after PBSC Transplant

    September 2016
    Lee SJ, et al. JAMA Oncol – A secondary analysis of 195 recipients from the randomized, multi-center (n=551) Blood and Marrow Transplant Clinical Trials Network trial (BMT CTN 0201), found that bone marrow (BM) recipients experienced significantly better psychological well-being and less burdensome chronic GVHD symptoms five years after HCT than peripheral blood stem cell (PBSC) recipients did.

    Read More

  • Pre-HCT Genetic Profiling Can Identify AML Patients at Increased Risk for Relapse

    September 2016
    Luskin MR, et al. Biol Blood Marrow Transplant – Researchers used next generation sequencing (NGS) of 26 genes and found mutations in TP53, WT1 and FLT3-ITD were associated with an increased risk of acute myeloid leukemia (AML) relapse after HCT (adjusted Hazard Ratio [aHR] 2.90, p=0.009; aHR 2.51, p=0.02; and aHR 1.83, p=0.07, respectively).

    Read More

  • TKIs Can Effectively Treat Post-Transplant Relapse Risk in Patients with Ph+ ALL

    September 2016
    Lussana F, et al. Biol Blood Marrow Transplant – Researchers analyzing prospective data from two consecutive clinical trials have demonstrated that patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) with measurable pre-transplant levels of minimal residual disease (MRD) have a significantly higher risk of relapse.

    Read More

  • Pre-Transplant Emotional Support Contributes to Longer Survival

    September 2016
    Ehrlich KB, et al. Bone Marrow Transplant – Researchers have found that good pre-transplant emotional support predicts longer overall survival at 2 years.

    Read More

  • Higher Post-Relapse Survival with Related or Unrelated HCT than Haploidentical HCT

    August 2016
    Solh M, et al. Bone Marrow Transplant – This single-center study of 237 consecutive patients who relapsed after HCT found that one-year post-relapse survival (PRS) was significantly higher in patients receiving matched related and matched unrelated grafts compared to those receiving haploidentical donor transplants using post-transplant cyclophosphamide.

    Read More

  • Biomarker Panel Can Predict Risk of Chronic GVHD

    August 2016
    Yu J, et al. J Clin Oncol – Researchers analyzing plasma samples of 53 HCT recipients identified 4 proteins that when used in a biomarker panel was prognostic of developing chronic graft-versus-host disease (cGVHD).

    Read More

  • Use of TKIs to Prevent Relapse after HCT for Patients with Ph+ ALL

    July 2016
    Giebel S, et al. Cancer – This consensus report from the European Society for Blood and Marrow Transplantation (EBMT) gives an overview of clinical studies on the use of tyrosine kinase inhibitors (TKIs) to prevent relapse after allogeneic HCT for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

    Read More

  • Improved Survival Over Time in Pediatric HCT

    July 2016
    Svenberg P, et al. Ped Transplant – A long-term study of pediatric allogeneic transplants found that outcomes improved over time, with significantly improved overall survival (OS) in transplants performed in the 2003-2013 time period compared to those performed in 1992-2002.

    Read More

  • Comparable Survival, More GVHD Risk Using EBV-Seropositive HCT Donors

    July 2016
    Styczynski J, et al. J Clin Oncol – A large-scale retrospective study of the effect of Epstein-Barr virus (EBV) serostatus on outcomes of allogeneic HCT in 11,364 patients with acute leukemia found that patients receiving grafts from EBV-seropositive donors had the same overall survival as patients who received grafts from EBV-seronegative donors.

    Read More

  • Study Confirms Effective Treatment of Veno-Occulusive Disease Using Defibrotide

    July 2016
    Strouse C, et al. Biol Blood Marrow Transplant – A large-scale retrospective study found that treatment with defibrotide can be an effective treatment for post-HCT veno-occlusive disease (VOD) and severe VOD (VOD with multi-organ failure).

    Read More

  • Sustained Long-Term Financial Burden of Allo-HCT on Patients/Caregivers

    May 2016
    Denzen EM, et al. Bone Marrow Transplant – Results of a 2-year pilot study of 16 allogeneic HCT recipients and their caregivers found that only half of patients who contributed to household income prior to HCT returned to work and a significant portion still faced financial challenges at least 2 years post-HCT.

    Read More

  • Review: HCT Vaccination Guidelines

    April 2016
    Carpenter PA, et al. Blood – In this installment of the “How I treat …” series in Blood, the authors present a concise practical review of vaccination guidelines for HCT recipients.

    Read More

  • Reduced Risk of Chronic GVHD with Post-Transplant Cyclophosphamide

    April 2016
    Mielcarek M, et al. Blood – High-dose cyclophosphamide administered after peripheral blood stem cell (PBSC) transplantation can reduce the risk of chronic graft-versus-host disease (GVHD), according to a single-center study of 43 patients.

    Read More

  • Higher Rates of Infection after Marrow Compared to PBSC Transplants

    April 2016
    Young J-A H, et al. Biol Blood Marrow Transplant – A study of unrelated donor hematopoietic cell transplantation (HCT) recipients in a phase 3 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trial has shown that bone marrow graft recipients had higher rates of bacterial and pre-engraftment infections than did peripheral blood stem cell (PBSC) recipients.

    Read More

  • Low Incidence of Late Cardiovascular Complications after Pediatric HCT

    February 2016
    Duncan CN, et al. BMT Tandem Meetings abstract oral presentation, February 2016 – Serious cardiovascular (CV) late effects are uncommon in pediatric transplant survivors, according to a multi-center study of 661 children who underwent hematopoietic cell transplantation (HCT) for hematologic malignancy between 1995 and 2008.

    Read More

  • Children Under 3 Years Old Undergoing HCT Require Long-Term Monitoring for Late Effects

    February 2016
    Vrooman L, et al. BMT Tandem Meetings abstract oral presentation, February 2016 – A study of myeloablative hematopoietic cell transplantation (HCT) performed in children under 3 years old has found that although transplant-related mortality at 10 years is only 5%, recipients require monitoring for late complications.

    Read More

  • Risk Factors Identified for Post-HCT Depression, Fatigue

    February 2016
    Jim HSL, et al. Cancer – An analysis of long-term survivors of hematopoietic cell transplantation (HCT) has identified clinical risk factors for post-transplant depression and fatigue.

    Read More

  • Review: Maintenance with TKIs Post-Transplant in FLT3-ITD Positive AML

    February 2016
    Schiller GJ, et al. Biol Blood Marrow Transplant – This review discusses the clinical evidence on FLT3-specific tyrosine kinase inhibitors (TKIs) being used as post-transplant maintenance in patients with FLT3-ITD acute myelogenous leukemia (AML) who are at high-risk for disease relapse.

    Read More

  • Children’s Oncology Group: Long-Term Follow-Up Guidelines After Pediatric HCT

    February 2016
    Chow EJ, et al. Biol Blood Marrow Transplant – The Children’s Oncology Group (COG) has updated its Long-Term Follow-Up Guidelines for survivors of childhood, adolescent, and young adult cancer, including those undergoing autologous or allogeneic hematopoietic cell transplantation (HCT) and malignant and non-malignant diseases.

    Read More

  • Improved Outcomes in HCT Recipients with Acute GVHD Over Time

    January 2016
    El-Jawahri A, et al. Biol Blood Marrow Transplant – A retrospective analysis of 427 hematopoietic cell transplantation (HCT) recipients who develop grades III or IV acute GVHD has found that outcomes have improved over time, with significantly lower transplant-related mortality (TRM) and increased overall survival (OS) in more recent transplants.

    Read More

  • Quality of Life Better After Marrow Transplant Than After PBSC Transplant

    December 2015
    Lee SJ, et al. ASH oral presentation, December 2015 – A secondary analysis of the large-scale (n=551) Blood and Marrow Transplant Clinical Trials Network (BMT CTN) randomized study of unrelated donor bone marrow (BM) vs. peripheral blood stem cell (PBSC) transplant has found that BM recipients have better psychological well-being and less burdensome chronic GVHD symptoms than PBSC recipients.

    Read More

  • Meeting the Needs of HCT Recipients Transitioning from Childhood to Adulthood

    December 2015
    Cupit MC, et al. Bone Marrow Transplant – In this review, the authors use clinical vignettes to discuss the focused and specific survivorship needs of the growing pediatric and adolescent and young adult (AYA) populations after hematopoietic cell transplantation (HCT).

    Read More

  • Pre-Transplant Patient-Reported Physical Health Predicts Post-Transplant Mortality

    November 2015
    Wood WA, et al. Cancer – Pre-transplant patient-reported outcomes (PROs) on a physical health scale independently predicted overall mortality (hazards ratio, 1.40 per 10-point decrease; p<0.001) of 336 allogeneic and 310 autologous HCT recipients enrolled in the Blood and Marrow Transplant Clinical Trials Network 0902 protocol.

    Read More

  • Ruxolitinib Effective in Treating Steroid-Refractory GVHD

    September 2015
    Zeiser R, et al. Leukemia – Ruxolitinib therapy to treat corticosteroid-refractory acute and chronic graft-versus-host disease (GVHD) in transplant recipients can achieve response rates >80%, according to a multi-center study of 95 patients treated with this JAK1/2 inhibitor.

    Read More

  • Novel Agents for Consolidation and Maintenance Therapy After Auto-HCT for Multiple Myeloma

    August 2015
    Mohty M, et al. Bone Marrow Transplant – Substantial improvements in the depth of response prior to transplant has been seen with the use of novel agents such as proteasome inhibitors and immunomodulatory drugs.

    Read More

  • Review: Complementary and Alternative Medicine Use among HCT Recipients

    May 2015
    Chakraborty R, et al. Cancer — Clinicians are often reluctant to provide specific complementary and alternative medicine (CAM) therapy recommendations despite use by a growing group of HCT survivors.

    Read More

  • Haploidentical HCT with Cyclophosphamide for High-Risk Leukemias

    April 2015
    Symons H, et al. Oral presentation, BMT Tandem Meetings — Myeloablative transplants using T-cell-replete haploidentical grafts and post-transplant cyclophosphamide can result in a 2-year overall survival (OS) of 57%, with cumulative incidence of relapse reaching 44% at 3 years according to results of a phase II study presented at the BMT Tandem Meetings.

    Read More

  • Outcomes of Extracorporeal Photopheresis Better in Early Stage GVHD

    April 2015
    Berger M, et al. Transfusion — A study of extracorporeal photopheresis (ECP) in 71 patients has shown that the procedure is effective in treating steroid-refractory or -dependent acute GVHD or chronic GVHD with lower severity in the early stages.

    Read More

  • New Guidelines for Secondary Solid Cancer Screening Following HCT

    April 2015
    Inamoto Y, et al. Bone Marrow Transplant — The incidence of secondary malignancies rises after HCT, with the most common occurrences in the oral cavity, skin, breast, and thyroid, according to this consensus report from CIBMTR and EBMT.

    Read More

  • Validated Chronic GVHD Risk Score Can Predict Major HCT Outcomes

    March 2015
    Arora M, et al. Biol Blood Marrow Transplant — A chronic graft-versus-host disease (GVHD) risk score, used to predict mortality in patients with GVHD, has now been validated by additional analysis of 1,128 patients with chronic GVHD transplanted between 2005 and 2007.

    Read More

  • AZA, DLI Effective Therapy for MDS, AML with Low Disease Burden

    March 2015
    Schroeder T, et al. Biol Blood Marrow Transplant — Results of a multicenter analysis have found that azacitidine (AZA) and donor lymphocyte infusions (DLI) can be a successful therapy for relapse after allogeneic HCT.

    Read More

  • Post-HCT Fungal and Viral Infections: Improving Outcomes over Time

    February 2015
    Parody R, et al. Bone Marrow Transplant — This retrospective analysis comparing post-transplant infections in cord blood (n=65) and bone marrow/PBSC transplant recipients (n=369) found that although cord blood transplantation was associated with a higher risk of invasive aspergillosis and cytomegalovirus infections, infection-related mortality was comparable in the two types of transplants.

    Read More

  • Review: Collaborative Partnerships to Manage Patients with Chronic GVHD

    January 2015
    Flowers MED, et al. Blood — In this review titled “How we treat chronic graft-versus-host disease” the authors outline their strategies for treating chronic GVHD, emphasizing that transplant center physicians and the hematology and oncology specialists who offer ongoing supportive care need to be collaborative partners to best manage their patients who develop chronic GVHD.

    Read More

  • Post-Transplant Cyclophosphamide Yields Comparable Outcomes Across Donor Types and Conditioning Regimens

    December 2014
    McCurdy SR, et al. ASH abstract oral presentation, December 2014 — Adults transplanted for advanced or poor-risk hematologic malignancies can have comparable outcomes using haploidentical, related donor, or unrelated donor grafts when high-dose post-transplant cyclophosphamide is administered to reduce graft-versus-host-disease (GVHD), according to study results presented at ASH.

    Read More

  • Long-Term Impact of TBI on Cognitive Functioning in Pediatric HCT

    November 2014
    Willard VW, et al. J Clin Oncol — Using total-body irradiation (TBI) in pre-transplant conditioning regimens lowers cognitive ability, according to a study of 315 pediatric hematopoietic cell transplant (HCT) recipients.

    Read More

  • HCT Prognostic Index Guides Clinical Decision-Making

    November 2014
    Sorror ML, et al. J Clin Oncol — New research into a composite prognostic index combining age and comorbidities has validated the utility of the index to guide clinical decision-making in HCT.

    Read More

  • Review Series in Blood Journal: Advances in HCT

    August 2014
    Negrin RS, et al. Blood — Scientific and clinical translational research highlighting treatment advances in the field of HCT are available in five review articles in Blood.

    Read More

  • Younger, Older HCT Recipients Have Comparable QOL

    August 2014
    Hamilton BK, et al. Bone Marrow Transplant — Older transplant recipients experienced comparable quality of life (QOL) when compared with younger recipients, according to a new prospective study of 351 transplant recipients surveyed between 2003 and 2010.

    Read More

  • Tacrolimus-Sirolimus Comparable to Tacrolimus-Methotrexate as GVHD Prophylaxis

    August 2014
    Cutler C, et al. Blood – A phase 3 Blood and Marrow Transplant Clinical Trials Network (BMT CTN) study of 304 randomized patients demonstrated that tacrolimus and sirolimus (Tac/Sir) was comparable to tacrolimus and methotrexate (Tac/Mtx) in preventing acute GVHD and early mortality after related donor hematopoietic cell transplantation (HCT).

    Read More

  • Review: Critical Need for Long-Term Follow-Up Care after HCT

    July 2014
    Hashmi S, et al. Biol Blood Marrow Transplant — Hematopoietic cell transplantation (HCT) recipients have a unique set of complications and late effects that require specialized care and preventive services to maximize long-term survival.

    Read More

  • Large-Scale Study Validates Prognostic Value of HCT Disease Risk Index

    May 2014
    Armand P, et al. Blood — A new study of 13,131 hematopoietic cell transplant (HCT) recipients whose outcomes were reported to the CIBMTR (Center for International Blood and Marrow Transplant Research) has validated the prognostic value of the Disease Risk Index (DRI).

    Read More

  • Pre-Transplant Comorbidities Predict Severity of Acute GVHD

    May 2014
    Sorror ML, et al. Blood — A multi-center study of 2,985 allogeneic transplants has demonstrated that the hematopoietic cell transplantation comorbidity index (HCT-CI) can predict the severity of graft-versus-host disease (GVHD) and subsequent mortality.

    Read More

  • Long-Term Study Shows HCT Survival Increasing over Time

    May 2014
    Malard F, et al. Biol Blood Marrow Transplant — This single-center study analyzed 827 allogeneic transplants and compared outcomes in three time periods: 1983-1990, 1991-2000, and 2001-2010.

    Read More

  • Geriatric Assessments Can Predict HCT Outcomes in Older Adults

    May 2014
    Muffly LS, et al. Haematologica — A geriatric assessment (GA) tool has independent prognostic utility in allogeneic HCT outcomes in patients aged 50 years and older, according to a study of 203 older adults.

    Read More

  • Review: Preserving Fertility in HCT Recipients

    April 2014
    Joshi S, et al. Bone Marrow Transplant - In this review, the authors note that the optimal time to address fertility issues in patients considering HCT is before the onset of therapy for the underlying disease, and that a referral to a reproductive specialist should be made for patients interested in fertility preservation.

    Read More

  • NCI Report: Prevention and Treatment of Relapse after Allo-HCT

    January 2014
    De Lima M, et al. Biol Blood Marrow Transplant - A report from the National Cancer Institute on the prevention and treatment of relapse after allogeneic transplantation.

    Read More

  • Peri-Transplant Rituximab in Lymphoma Can Lead to Durable Event-Free Survival

    December 2013
    Sauter CS, et al. Biol Blood Marrow Transplant - Non-myeloablative transplantation incorporating peri-transplant-rituximab can lead to a two-year event-free survival (EFS) of 72%, according to results of a prospective trial of 51 patients with CD20+ B-cell non-Hodgkin lymphoma.

    Read More

  • Imatinib to Treat Steroid-Refractory Chronic GVHD

    December 2013
    Olivieri A, et al. Blood - In this prospective trial, researchers administered imatinib to treat steroid-refractory chronic GVHD in 39 adult transplant recipients aged 28-73 years.

    Read More

  • Inhibition of IL-6 Can Offer “Profound Protection” from Acute GVHD

    December 2013
    Kennedy GA, et al. ASH abstract oral presentation, December 2013 – Grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) is significantly reduced in transplant recipients receiving a monoclonal antibody inhibiting interleukin-6 (IL-6), according to research results presented at ASH.

    Read More

  • Childhood HCT Survivors Require Life-Long Monitoring for High-Risk Complications

    December 2013
    Armenian S, et al. ASH abstract oral presentation, December 2013 – Pediatric hematopoietic cell transplant (HCT) recipients can experience high-risk health complications well into adulthood, and therefore require close monitoring, according to results of 317 pediatric HCT survivors participating in the Bone Marrow Transplant Survivor Study (BMTSS).

    Read More

  • Understanding Factors in Long-Term HCT Outcome in Fanconi Anemia

    November 2013
    Peffault de Latour RP, et al. Blood - The estimated 20-year survival of 795 Fanconi anemia (FA) patients who underwent first HCT between 1972 and 2010 is 49%, according to this multi-center study published in Blood.

    Read More

  • Personalized Prognostic Information for Adult Leukemia Survivors after HCT

    November 2013
    Lee SJ, et al. Biol Blood Marrow Transplant - By analyzing outcomes data of 3,339 adults with AML and 1,434 adults with ALL submitted to the CIBMTR, researchers have developed formulas to estimate future leukemia-free survival (LFS) of transplant recipients surviving one year or more post-transplant.

    Read More

  • Immune-Modulating Drugs, Hypomethylating Agents to Treat Relapse

    October 2013
    Kröger N, et al. Biol Blood Marrow Transplant - This review summarizes the current knowledge and potential use of immune-modulating drugs and hypomethylating agents in preventing or treating relapse after allogeneic HCT.

    Read More

  • Meta-Analysis: HCT Does Not Affect Cognitive Functioning in Adults

    October 2013
    Phillips KM, et al. Bone Marrow Transplant - A meta-analysis of 11 studies on HCT and cognitive functioning has found that cognitive functioning does not significantly change following HCT.

    Read More

  • Post-HCT Rituximab Prophylaxis Can Reduce Chronic GVHD

    September 2013

    Cutler C, et al. Blood. - In this trial of 65 patients, administering post-transplant rituximab (375 mg/m2 IV) at 3, 6, 9, and 12 months after transplantation resulted in significantly lower two-year cumulative incidence of systemic corticosteroid-requiring chronic graft-versus-host disease (GVHD) compared to a concurrent control group: 31% vs. 48.5% respectively (p=0.015).

    Read More

  • Report: Prophylaxis and Treatment of GVHD

    August 2013

    Ruutu T, et al. Bone Marrow Transplant - A working group formed by the European Group for Blood and Marrow Transplantation (EBMT) and European LeukemiaNet has developed recommendations for prophylaxis and treatment of acute and chronic GVHD.

    Read More

  • Lower Chronic GVHD in Double Cord Blood HCT

    August 2013
    Malard F, et al. Leukemia - Double cord blood and 9/10 matched unrelated donor reduced-intensity transplants have similar outcomes, but using cord blood results in a significantly lower incidence of chronic graft-versus-host disease (GVHD), according to a study of 152 patients (median age 53 years) transplanted for hematological malignancies.

    Read More

  • Long-Term Follow-Up of HCT Recipients Made Easier

    July 2013
    Majhail NS, et al. Bone Marrow Transplant - A summary of the updated screening and preventive practices guidelines for HCT recipients focusing on ways that health care providers can effectively integrate the guidelines into clinical practice.

    Read More

  • How I Treat Older Patients with ALL

    June 2013
    Gökbuget N. Blood - In this installment of the “How I Treat” series in the journal Blood, Dr. Nicola Gökbuget outlines how improved supportive care, targeted therapies, moderately intensified consolidation, and reduced-intensity hematopoietic cell transplantation have improved outcomes somewhat for older patients with acute lymphoblastic leukemia (ALL).

    Read More

  • Long-Term Follow-Up of Caregivers for HCT recipients

    April 2013

    Wulff-Burchfield EM, et al. Bone Marrow Transplant - This article provides an overview of the long-term physical and psychosocial issues affecting caregivers: the spouses, partners, and/or children of hematopoietic cell transplant recipients.

    Read More

  • New Autoimmune Diseases after Cord Blood Transplantation

    January 2013
    Daikeler T, et al. Blood - An analysis of 726 cord blood transplants reported to the European cord blood transplant database has found that the cumulative incidence of autoimmune disease developing post-transplant in these patients was 5.0% at 1 year and 6.6% at 5 years.

    Read More

  • Marrow, PBSC Have Comparable Survival; More cGVHD with PBSC

    November 2012

    Anasetti C, et al. N Eng J Med - A phase III, multi-center, randomized trial comparing peripheral blood stem cells (PBSC) and bone marrow transplant outcomes has found comparable 2-year survival.

    Read More

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma